We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Substitute for Estrogen Without the Risks

By Biotechdaily staff writers
Posted on 08 Jan 2004
Scientists have developed a new selective estrogen receptor modulator (SERM) called STX that shows promise as an alternative to estrogen treatment for symptoms of menopause while lacking the side effects and risks. More...
Their work was reported in the October 22, 2003, issue of The Journal of Neuroscience.

STX mimics the effects of estrogen by activating a novel rapid signaling pathway in nerve cells of the hypothalamus, which controls functions such as ovulation, lactation, body temperature, and energy balance. It avoids the uterus and breasts, whose growth is stimulated by estrogen through a different pathway, leading to increased cancer risk. STX is structurally distinct from SERMS such as tamoxifen and raloxifene, and is about 10 times more potent than estrogen. Thus, it has the potential to be more effective at maintaining cognitive performance of postmenopausal women.

"The function of STX was really identified from our electrophysiological assay based on testing different (SERM) compounds that acted like estrogen in the central nervous tissue, but not in other tissues susceptible to the cancer-causing effects of estrogens,” said Martin J. Kelly, Ph.D., professor of physiology and pharmacology at Oregon Health & Science University (Portland, USA). "Women who don't have hormone replacement therapy have been known to have more cognitive impairment in terms of loss of memory, and a higher incidence of Alzheimer's disease.”




Related Links:
Oregon Health & Science U.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.